Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

被引：27

作者：

Biemans, Vince B. C. ^{[1
,2
]}

van der Woude, C. Janneke ^{[3
]}

Dijkstra, Gerard ^{[4
]}

van der Meulen-de Jong, Andrea E. ^{[5
]}

Oldenburg, Bas ^{[6
]}

de Boer, Nanne K. ^{[7
,8
]}

Loewenberg, Mark ^{[9
]}

Srivastava, Nidhi ^{[10
]}

Bodelier, Alexander G. L. ^{[11
]}

West, Rachel L. ^{[12
]}

Jansen, Jeroen M. ^{[13
]}

de Vries, Annemarie C. ^{[3
]}

Haans, Jeoffrey J. L. ^{[2
]}

de Jong, Dirk J. ^{[1
]}

Pierik, Marie J. ^{[2
]}

Hoentjen, Frank ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Dept Gastroenterol & Hepatol, Med Ctr, Nijmegen, Netherlands

[2] Maastricht Univ, Dept Gastroenterol & Hepatol, Med Ctr, Maastricht, Netherlands

[3] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[4] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands

[5] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands

[6] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands

[7] Vrije Univ, Amsterdam Univ, Dept Gastroenterol & Hepatol, Med Ctr, Amsterdam, Netherlands

[8] Amsterdam Gastroenterol & Metab Res Inst, Amsterdam, Netherlands

[9] Univ Amsterdam, Dept Gastroenterol & Hepatol, Med Ctr, Acad Med Ctr, Amsterdam, Netherlands

[10] Haaglanden Med Ctr, Dept Gastroenterol & Hepatol, The Hague, Netherlands

[11] Amphia Hosp, Dept Gastroenterol & Hepatol, Breda, Netherlands

[12] Franciscus Gasthuis & Vlietland, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[13] Onze Lieve Vrouw Hosp, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷 / 05期

关键词：

LONG-TERM EFFECTIVENESS; MAINTENANCE THERAPY; MULTICENTER COHORT; INDUCTION; SAFETY; IMPACT;

D O I：

10.1002/cpt.1712

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index <= 4, Short Clinical Colitis Activity index <= 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression.

引用

页码：1189 / 1199

页数：11

共 50 条

[1] Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Straatmijer, T.
Biemans, V. B. C.
Hoentjen, F.
de Boer, N. K. H.
Bodelier, A. G.
Dijkstra, G.
van Dop, W.
Haans, J. J. L.
Jansen, J. M.
Maljaars, P. W. J.
van der Marel, S.
Oldenburg, B.
Ponsioen, C. Y.
Visschedijk, M. C.
de Vries, A. C.
West, R.
van der Woudeu, C. J.
Pierik, M.
Duijvestein, M.
van der Meulen-de Jong, A. E.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S319 - S319
[2] Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Straatmijer, Tessa
Biemans, Vince B. C.
Hoentjen, Frank
de Boer, Nanne K. H.
Bodelier, Alexander G. L.
Dijkstra, Gerard
van Dop, Willemijn A.
Haans, Jeoffrey J. L.
Jansen, Jeroen M.
Maljaars, P. W. Jeroen
van der Marel, Sander
Oldenburg, Bas
Ponsioen, Cyriel Y.
Visschedijk, Marijn C.
de Vries, Annemarie C.
West, Rachel L.
van der Woude, C. Janneke
Pierik, Marieke
Duijvestein, Marjolijn
van der Meulen-de Jong, Andrea E.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 (11): : 1920 - 1930
[3] Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
Biemans, V.
van der Woude, J.
Dijkstra, G.
van der Meulen-de Jong, A.
Oldenburg, B.
de Boer, N.
Lowenberg, M.
Srivastava, N.
Jansen, J.
West, R.
de Vries, A.
Haans, J.
Pierik, M.
Hoentjen, F.
[J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S363 - S364
[4] TWO YEAR EXPERIENCE WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF THE ICC CASE SERIES, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDY
Biemans, Vince
Van der Woude, Christien Janneke
Dijkstra, Gerard
Meulen-de Jong, Andrea V.
Oldenburg, Bas
de Boer, Nanne
Lowenberg, Mark
Srivastava, Nidhi
Jansen, Jeroen M.
West, Rachel
de Vries, Annemarie C.
Haans, Jeoffrey
Pierik, Marie
Hoentjen, Frank
[J]. GASTROENTEROLOGY, 2019, 156 (06) : S884 - S884
[5] Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Biemans, Vince B. C.
van der Meulen-de Jong, Andrea E.
van der Woude, Christine J.
Lowenberg, Mark
Dijkstra, Gerard
Oldenburg, Bas
de Boer, Nanne K. H.
van der Marel, Sander
Bodelier, Alexander G. L.
Jansen, Jeroen M.
Haans, Jeoffrey J. L.
Theeuwen, Rosaline
de Jong, Dirk
Pierik, Marie J.
Hoentjen, Frank
[J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 (01): : 33 - 45
[6] TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF THE ICC REGISTRY, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDY
Biemans, Vince
Sleutjes, Jasmijn A.
de Vries, Annemarie C.
Bodelier, Alexander
Dijkstra, Gerard
Oldenburg, Bas
Lowenberg, Mark
van Bodegraven, Adriaan A.
Meulen-de Jong, Andrea V.
de Boer, Nanne
Srivastava, Nidhi
West, Rachel
Romkens, Tessa
Horje, Carmen S. Horjus Talabur
Jansen, Jeroen M.
Hoekstra, Jildou
Weersma, Rinse K.
van Schaik, Fiona
Hoentjen, Frank
Pierik, Marie
[J]. GASTROENTEROLOGY, 2020, 158 (06) : S1206 - S1207
[7] Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Biemans, V. B.
Sleutjes, J. A. M.
de Vries, A. C.
Bodelier, A. G.
Dijkstra, G.
Oldenburg, B.
Lowenberg, M.
van Bodegraven, A. A.
van der Meulen-de Jong, A. E.
de Boer, N. K.
Srivastava, N.
West, R. L.
Romkens, T.
Horje, C. S. Horjus Talabur
Jansen, J. M.
Hoekstra, J.
Weersma, R. K.
van Schaik, F. D.
Hoentjen, F.
Pierik, M. J.
[J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S097 - S098
[8] Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Biemans, Vince B. C.
Sleutjes, Jasmijn A. M.
Vries, Annemarie C.
Bodelier, Alexander G. L.
Dijkstra, Gerard
Oldenburg, Bas
Lowenberg, Mark
Bodegraven, Adriaan A.
van der Meulen-de Jong, Andrea E.
Boer, Nanne K. H.
Srivastava, Nidhi
West, Rachel L.
Romkens, Tessa E. H.
Horje, Carmen S. Horjus Talabur
Jansen, Jeroen M.
van der Woude, C. Janneke
Hoekstra, Jildou
Weersma, Rinse K.
van Schaik, Fiona D. M.
Hoentjen, Frank
Pierik, Marieke J.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) : 880 - 888
[9] Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study
Straatmijer, T.
Visschedijk, M.
de Vries, A.
Hoentjen, F.
van Bodegraven, A. A.
Bodelier, A. G. L.
de Boer, N. K. H.
Dijkstra, G.
Festen, E. A. M.
Horjus, C.
Jansen, J. M.
Jharap, B.
Mares, W.
Oldenburg, B.
Ponsioen, C. Y.
Romkens, T. E. H.
Srivastava, N.
van der Voorn, M. M.
West, R. L.
van der Woude, J. C.
Wolvers, M. D. J.
Pierik, M.
van der Meulen, A. E.
Duijvestein, M.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I119 - I120
[10] DRUG SURVIVAL OF VEDOLIZUMAB-TREATED INFLAMMATORY BOWEL DISEASE PATIENTS IN A NATIONWIDE OBSERVATIONAL COHORT STUDY: ICC CASE SERIES
Biemans, Vince
Van der Woude, Christien Janneke
Dijkstra, Gerard
Van der Meulen, Andrea
Oldenburg, Bas
de Boer, Nanne
Ponsioen, Cyriel
de Vries, Annemarie C.
Haans, Jeoffrey
Pierik, Marie
Hoentjen, Frank
[J]. GASTROENTEROLOGY, 2018, 154 (06) : S838 - S838

← 1 2 3 4 5 →